Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneMichael Gnant, Torsten O. Nielsen, Christian F. Singer et al.|Annals of Oncology|2013Cited by 403
The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Torsten O. Nielsen, Margaretha Rudas et al.|Clinical Cancer Research|2014Cited by 219
Data from The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Michael Gnant, Torsten O. Nielsen et al.|Unknown|2023Cited by 0
Supplementary Table 1 from The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Michael Gnant, Torsten O. Nielsen et al.|Unknown|2023Cited by 0
Supplementary Table 1 from The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Michael Gnant, Torsten O. Nielsen et al.|Unknown|2023Cited by 0